PeptideDB

CAY10746

CAS: 2247240-76-0 F: C26H23N3O5 W: 457.48

CAY10746 is a selective Rho kinase (ROCK) inhibitor. CAY10746 has inhibitory activity for ROCK I, ROCK II with IC50 valu
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity CAY10746 is a selective Rho kinase (ROCK) inhibitor. CAY10746 has inhibitory activity for ROCK I, ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be used for the research of diabetic retinopathy (DR)[1].
Target IC50: 0.014 μM (ROCK I); 0.003 μM (ROCK II)
Invitro CAY10746 (compound 12j) 对 ROCK I、ROCK II 具有抑制活性,IC50 值分别为 0.014 μM 和 0.003 μM[1]。CAY10746(0.1、1 和 10 μM;0.25、1、2 和 4 h)抑制 SH-SY5Y 细胞中的 ROCK 激酶活性[1]。CAY10746(1 μM;24 h、36 h)在体外抑制内皮细胞迁移[1]。CAY10746(1 μM;5 days)保护视网膜神经元免受高葡萄糖诱导的氧化应激和细胞凋亡介导的细胞死亡[1]。CAY10746(1 μM;5 days)抑制 Müller 细胞的不当增殖并促进在高糖微环境中培养的视网膜外植体中的血管退化[1]。 Western Blot Analysis[1] Cell Line:
Name CAY10746
CAS 2247240-76-0
Formula C26H23N3O5
Molar Mass 457.48
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Lanying Zhao, et al. Discovery of 4 H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models. J Med Chem. 2019 Dec 12;62(23):10691-10710.